Browse All

Current Filters

CLEAR FILTER x

TITLE

National Mortality Trends and Forecasts of Parkinson’s Disease With Psychiatric Comorbidities Among Older Adults in the United States,1999–2023

Author:Chaudhary, Kanchan   Zaheer, Minahil   Chauhan, Anchit   Zubair, Ali   umar, Muneeba   Malik, Tayyaba   Cherukuri, Anjani Mahesh Kumar   

Session Name:P3: Movement Disorders: Parkinson's Disease Epidemiology  

Topic:Movement Disorders  

Program Number:P3.010  

Author Institution:liaquat university of medical and health sciences jamshoro pakistan, Umerkot, Pakistan  Hbs medical and dental college Islamabad Pakistan , Rawalpindi, Pakistan  Maulana Azad Medical College, New Delhi, India , Kurukshetra, India  sheikh zayed medical college raheem yar khan, pakistan, Khanewal, Pakistan  HBS Medical & Dental College , Islamabad , Islamabad, Pakistan  Jinnah Sindh Medical University, Karachi,pakistan, Karachi, Pakistan  : Guntur Medical College, Guntur, India , Guntur, India  

Low Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON Study: Effect of Levodopa Dose

Author:Ferreira, Joaquim   Rascol, Olivier   Stocchi, Fabrizio   Antonini, Angelo   Dias, Bruno   Rocha, Francisco   Ramos, Daniel   Banisadr, Ghazal   Brigas, Helena   Holenz, Joerg   Poewe, Werner   

Session Name:P3: Movement Disorders: Parkinson's Disease Management 1  

Topic:Movement Disorders  

Program Number:P3.010  

Author Institution:Universidade Lisboa, Torres Vedras, Portugal  University of Toulouse, University Hospital of Toulouse, INSERM, Clinical Investigation Center CIC1436, Toulouse, France  IRCCS San Raffaele Pisana, Rome, Italy  University of Padova, Italy  BIAL – Portela & Ca S.A., Portugal  BIAL – Portela & Ca S.A. , Portugal  Amneal Pharmaceuticals, Evanston, IL  BIAL – Portela & Ca S.A., CORONADO (S. Romão E S. Mamede, Portugal  BIAL – Portela & Ca S.A., Coronado, Portugal  Medical University of Innsbruck, Innsbruck, Austria  

Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in People with Advanced Parkinson’s Disease in Two Phase Three Clinical Trials

Author:Hauser, Robert   Antonini, Angelo   Garbin Di Luca, Daniel   Freire Alvarez, Eric   Oliveira Fernandes, Michelle   Shah, Megha   Bergmann, Lars   Gupta, Resmi   O'Meara, Marie   Standaert, David   

Session Name:P3: Movement Disorders: Parkinson's Disease Management 1  

Topic:Movement Disorders  

Program Number:P3.011  

Author Institution:University of South Florida Parkinson’s Disease and Movement Disorders Center of Excellence, Tampa, FL  University of Padova, Italy  Washington University in St. Louis, St. Louis, MO  Hospital General Universitario of Elche, Elche, Spain  AbbVie Inc., Mettawa, IL  University of Alabama At Birmingham, Birmingham, AL  

Prevalence of Pathogenic CSF1R Variants in a Large Genomic Cohort: Insights from the Mayo Tapestry Study

Author:Milanowski, Lukasz   Chmiela, Tomasz   Tacik, Pawel   Olson, Rory   Ross, Owen   Wszolek, Zbigniew   

Session Name:P3: Movement Disorders: Parkinson's Disease Epidemiology  

Topic:Movement Disorders  

Program Number:P3.011  

Author Institution:Mayo Clinic, Jacksonville, FL  Mayo Clinic, MN  

Effect of Opicapone on Sleep-related Complaints and Non-motor Burden in Parkinson’s Patients: A Post-hoc Analysis of the OASIS Trial

Author:Gago, Miguel   Costa, Raquel   Brigas, Helena   Dias, Bruno   Banisadr, Ghazal   Holenz, Joerg   Ferreira, Joaquim J.   

Session Name:P3: Movement Disorders: Parkinson's Disease Management 1  

Topic:Movement Disorders  

Program Number:P3.012  

Author Institution:Hospital da Senhora da Oliveira, Guimarães, Guimarães, Portugal  BIAL – Portela & Ca S.A., Coronado (S. Romão e S. Mamede), Portugal  BIAL – Portela & Ca S.A., CORONADO (S. Romão E S. Mamede, Portugal  BIAL – Portela & Ca S.A., Portugal  Amneal Pharmaceuticals, Evanston, IL  BIAL – Portela & Ca S.A., Coronado, Portugal  Universidade Lisboa, CNS-Campus Neurológico, Lisboa, Portugal